Plasma-adapted balanced solution of electrolytes

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of pharmaceutics and deals with application of aqueous balanced solution of electrolytes as external washing solution, for washing and purification in case of surgery, for washing and purification of wounds and burns, for washing body cavities, for eye washing, for washing and purification of instruments and in servicing stomas or as carrier solution for compatible electrolytes, nutrients and medications. Aqueous balanced solution contains: 138-146 mmol/l of sodium, 4-5 mmol/l of potassium, 0.5-2.0 mmol/l calcium, 1.0-1.5 mmol/l of magnesium, 100-108 mmol/l of chloride, 0.5-1.5 mmol/l of phosphate, 18-26 mmol/l of gluconate, 20-28 mmol/l of acetate.

EFFECT: invention makes it possible to use aqueous balanced solution as effective means of external washing solution or as carrier solution for compatible electrolytes, nutrients and medications.

11 cl, 2 tbl, 4 ex

 

The present invention relates to an aqueous balanced electrolyte solution. This invention relates, in particular, to water a balanced electrolyte solution that for the reason that it is adapted to the plasma, is particularly suitable as a solution for intravenous and subcutaneous infusions. This, along with a balanced electrolyte solution is a mixture of electrolytes, together with a way of obtaining a balanced electrolyte solution, and a medicament which includes this solution, and optionally the active substance.

Intravenous administration of saline to the patient ("drip") is the most frequent infusion treatment, which is carried out in the preclinical area in case of accidents and accidents in the clinical area (nationwide), in practice, ambulatory care, and, increasingly, institutions of elderly care. This introduction produced when patients there is an acute lack of a liquid extracellular space, patients can quickly be removed with drinking, if desired or necessary, as, for example, due to the violation of the sensation of thirst or necessary immobilization of the digestive tract. In particular, these salt dissolve�s pour in for to align acute fluid loss that would be caused, for example, vomiting or diarrhoea, or to compensate for a deficiency of fluid in the circulation due to shock or blood loss. The last commit only for a time, until you arrive in the order of colloid that fills a volume of blood, fluids or blood products. When used in all these cases salt solutions with an emphasis on balanced electrolyte solutions, i.e. those solutions, which ideally should contain all the electrolytes that also exist in human plasma, namely in the same proportions, as well as effective osmotic concentrations.

Further, these salt solutions are used in large volume in order to dilute or dissolve them in medications, nutrients or additional mineral substances, which must be administered intravenously, and in order to do the infusion with a certain constant velocity ("media solutions").

Such infusion treatment in today's understanding it was sold only in the 20th century and has also been adopted by large-scale over the II-nd world war. Of course, for a long time infusion solutions in the clinics of Europe before applying independently of sexualiy was heated for sterilization. Later solutions were standardized and prepared in the appropriate clinical pharmacies. In the last three decades, these solutions because of material costs, mainly produce industrial way (W. Druml, Wien. Klin Wochenschr. 2005, 117/3, 67-70).

The problem in obtaining and compiling recipes such balanced electrolyte solutions to replace the extracellular fluid and electrolytes is that one side should largely mimic the physiological pattern of plasma electrolyte, namely, respectively, of concentrations of cations (sodium, potassium, calcium and magnesium) and anions (chloride, phosphate and bicarbonate) [Zander et al., Anästhesiol. Intensivmed. Notfallmed. Schmerzther. 2005, 40, 701-719], on the other hand, however, it is necessary to consider the restrictions that come with technological and clinical side. For some reason, such as, in particular, the instability of bicarbonate in the high temperature sterilization and because of the use of conventional plastic container, the requirement of identity with the plasma can only be performed conditionally. Ultimately, it is possible through what is bicarbonate or, respectively, its theoretically suitable salts, are used as such intermediates bicarbonate. For this purpose suitable organic anions such as lactate, the ACO�the at or other, which only the infusion in the body metabolization to bicarbonate and thus provide it. Despite associated with the absence or, respectively, with the replacement of bicarbonate difficulties, the osmotic pressure of the solution must match the osmotic pressure of blood plasma in order to avoid unwanted movement of fluid between intracellular and extracellular spaces. Furthermore, intended for intravenous infusion solutions, to ensure good local compatibility with the infusion can have significant acidity or alkalinity and, on this basis, they should be drafted in such a way that they didn't change the physiological acid-base balance. And, finally, the problem is that blood plasma contains certain protein bodies, which are not provided with any components of balanced electrolyte solutions, the negative charge which is necessary because of electroneutrality, however, requires the presence of counterions, which are free from proteins in solution, electrolytes are not reproduced in the same form.

Therefore, all currently in use balanced electrolyte solutions are a compromise between the requirement of perfect identity of the plasma and is actually present in the presence of Sol�re combination of electrolytes, that do not serve the other aforementioned requirements, or implement them fully. The discrepancy between the ideal and the actual composition is facilitated by the fact that any effort to implement identity in the individual elements will inevitably lead to neglect of other elements.

Due to the above historical development, during which infusion solutions at the local level independently produced in the clinics, at the moment there are many different formulations of infusion solutions, each with their own way are trying to cope with the aforementioned problems. In this case, primarily for production-technical reasons, such as ease of fabrication and low cost, as the most common infusion solution infusion in the treatment of established 0.9% sodium chloride solution. Further, there are solutions, which, along with sodium chloride contain additional electrolytes, such as named after their creators solutions ringer's and Hartmann's and ringer-Lactate solution (RL), which is known as Hartman's solution contains lactate ions. In table 1 the data structures of infusion solutions opposed to the content of electorlytes in human plasma (J. Boldt, Transfusion Alternatives in Transfusion Mediane, 2007, 9, 189-197).

Table 1
The compositions of different infusion solutions. The formulations vary by manufacturer and country of origin
ElectrolytePlasma0.9% NaClRingerRLPlasmalyte 148Hartman
Na+[mmol/l]140154154131140129
K+[mmol/l]4,2-4,05,455
Ca2+[mmol/l]2,5-2,31,8-4
Mg2+[mmol/l]3--0,53 -
Phosphate [mmol/l]1,25-----
Cl-[mmol/l]10315416311298109
Lactate [mmol/l]1--27-29
Acetate [mmol/l]----27-
Na+/Cr-ratio1,361,00,941,171,421,18

As can be seen from Table 1, compared with the composition of the plasma, these solutions are partly physiological, as they consist of not physiological, that is, from n�according to the quantitative ratio in the blood plasma, a mixture of electrolytes, or show different from the blood plasma osmotic pressure or have other differences.

In addition, a relatively significant side effects of these solutions, and, accordingly, reported complications in the use of these infusion solutions. Thus, there are significant changes in acid-base balance of patients who are pouring large amounts of such salt solutions that do not contain bicarbonate or, respectively, in which the content of chloride relative to sodium content higher than that of blood plasma. This phenomenon, depending on the diagnosis, classify as "diluted acidosis" or as "giperhloremiceski acidosis".

As indicated above, the absence of bicarbonate to compensate for it is through the application of certain organic anions that are metabolized to bicarbonate and replace it with a secondary method, however, the necessary amounts of organic anions is smaller than it would be desirable to reduce the content of inorganic anions such as chloride to the limit identical to the plasma. Therefore, giperhloremiceski acidosis with partial replacement of chloride anions with providing organic anions bicarbonate or remains not completely prevented, or when the more high�fir concentrations providing bicarbonate anions there is a risk of alkalosis, as a consequence infusion properly made infusion solutions.

Cause other complications partly lies in the fact that the osmotic pressure of many currently used solutions of electrolytes may be lower than that of blood plasma and contains more of the so-called "free water". Under the "free water" refers to fluid that is not associated with the corresponding ions. When intravenous infusion of "free water" more penetrates the tissues of the body and contributes there to the formation of accumulations of fluid ("edema"). Brain cells are particularly susceptible respond to changes in emotionaly, resulting in cerebral symptoms, which can range from drowsiness to encephalopathy or coma. Especially in premature and newborn children unlike adults disproportionately high percentage of brain mass relative to the entire weight of the body, especially it could lead to brain swelling. When you receive large masses of "free water" in the form of hypotonic IV solutions or solutions with too low osmotic pressure than the osmotic pressure of blood plasma in Pediatrics described even cases of death (A. I. Arieff, Paediatric Anaesthesia, 1998, 8, 1-4). At particular risk are patients with traumatic brain injury, as there is a risk gain edema� of the brain or increase the pressure of the brain, if they are treated with hypotonic intravenous fluids. A typical representative of hypotonic infusion solutions, for example, is widespread ringer-Lactate solution. The following is associated with possible complications disadvantage of this type of solution is that contained in the solution not lactate can be metabolized to bicarbonate if there is severe liver damage, which often occurs in critically ill intensive patients or patients in severe shock.

Further, known for such unwanted side effects during the infusion of commercially available infusion solutions, such as poor local tolerability and compatibility issues with added drugs. Designed and obtained suitable for infusions of electrolyte solutions, which correspond to the physiological profile of plasma electrolytes, passing in the method of producing sterilized by heating, having a good local tolerability and high compatibility with added drugs having the same osmotic pressure as plasma, and does not affect the acid-alkaline balance, therefore, are subject to University and commercial research.

Thus, in DE 3224823 A1 describes a method for obtaining optimized for the corresponding case�I diseases of electrolyte solution for use in hemodialysis. The assumption is made 9 l basic solution that contains a 45.5 g - EQ. sodium (Na+), 350 mEq. magnesium (Mg++), 12,25 g - EQ. acetate (CH3CO2-) and 33.6 g - EQ. chloride (Cl-), and not necessarily from 630 to 720 g of glucose. The desired final composition set through what is missing up to 10 l volume is filled up to the desired concentration values corresponding sterile standard 3.5 N solution of sodium chloride, potassium chloride, calcium chloride and/or magnesium acetate.

From EP 0613688 B2 became known method, which makes possible an individual adaptation of the composition of the fluid for dialysis for a variety of therapeutic needs through the use of primary concentrate, which mainly includes sodium chloride and sodium bicarbonate.

For the reasons described above it is desirable for the production of adapted to the plasma, and isotonic balanced electrolyte solution that possibly avoids the disadvantages of the existing balanced electrolyte solutions. Therefore, the object of this invention is to provide an isotonic, adapted to the plasma of a balanced electrolyte solution that does not cause due to infusion of electrolyte homeostasis and acid-base balance and has good local tolerability. Not�Jew was, that problem is solved with the help of water balanced electrolyte solution that is described in claim 1 of the claims. In addition, unexpectedly, an electrolyte solution according to the invention solves the above problems of the prior art and, in particular, does not cause local irritation of blood vessels or close to infusion of tissues.

Therefore, a first object of this invention is water balanced electrolyte solution with ions of (a) 138-146 mmol/l sodium, (b) 4-5 mmol/l potassium, c) from 0.5-2.0 mmol/l calcium, d) is 1.0-1.5 mmol/l magnesium, (e) 100-108 mmol/l chloride, f) of 0.5-1.5 mmol/l phosphate, g) 18-26 mmol/l gluconate and h) 20-28 mmol/l acetate.

In this case, the preferred option the implementation of a balanced electrolyte solution according to the invention is solutions which are, respectively, exist independently from each other with the content of ions in at least one of the following concentrations: (a) 140-144 mmol/l of sodium and/or (b) 4,3-4,7 mmol/l potassium and/or (c) is 1.0-1.5 mmol/l of calcium and/or (d) 1,1-1,4 mmol/l of magnesium and/or (e) 102 to 106 mmol/l of chloride and/or f) Of 0.8-1.2 mmol/l phosphate and/or (g) 20-24 mmol/l gluconate and/or (h) 22-26 mmol/l acetate.

Further, it is preferable that water balanced electrolyte solution had a pH-value within the range from 5.0 to 8.0, particularly preferably from 6.0 to 7.0. Further, it is preferable recommendation�yovanny an electrolyte solution according to the invention has an osmotic pressure of 280 to 300 mosmol ' /kg H 2O.

Turned out to be advantageous to prepare mixtures of electrolytes in solid form, which can be increased by dissolving in water to solutions of electrolytes according to the invention. This simplifies the transport, as it does not convey the weight and volume of solvent. Further, thereby achieve stability and stability during storage.

Following the subject of this invention is a mixture of electrolytes, ionic content (a) of 24.5-25.9 wt.% sodium, (b) to 1.21-1.51 wt.% potassium, (c) 0.15 to 0.61 wt.% calcium, (d) and 0.19 to 0.28 wt.% magnesium, (e) and 27.3-29.5 wt.% chloride, (f) 0.18 to 0.54 wt.% phosphate, g) of 27.1-39.1 wt.% gluconate and h) 9,10-12.7 wt.% acetate, and the data in wt.% respectively refer to the full weight of the mixture of the electrolyte.

According to the method of the invention is preferably such salt is used, which is recommended in a special prescription books and monographs, such as, among others, the European prescription book/European Pharmacopeia and United States Pharmacopeia.

Therefore, in a preferred embodiment of the used salt, which is selected from the group including chloride, sodium acetate × 3H2O hydrogen phosphate sodium × 2H2O, the sodium salt of D-gluconic acid, potassium chloride, potassium acetate, D-calcium gluconate × H2O and magnesium chloride × 6H2O.

The electrolyte mixture of the invention can be dissolved in water to adapt Zn�Chennai pH translate into the electrolyte solution according to the invention.

Therefore, the next subject of invention is a method of producing water full of electrolyte solution, which includes stages: (i) dissolving a mixture of electrolytes according to the invention in such an amount of water sufficient to set the molar concentration of the respective electrolytes; and (ii) setting the pH of the solution in the region from 5.0 to 8.0.

The electrolyte solution according to the invention, by reason of its adaptation to the plasma and balanced composition, isotone and hassle-free local tolerability is very well suited as an infusion solution, namely, not only within intravenous, and subcutaneous injections ("subcutaneous infusion"). Therefore an object of this invention is a method of applying water is full of electrolyte solution as an intravenous or subcutaneous infusion solution. As such solutions were found, these solutions can be used preferably for the treatment of hypotonic or isotonic dehydration, for the treatment of extracellular fluid loss, hypovolemia or shock, and for rehydration interstitial tissue after colloid replacement volume or as a solution carrier for compatible electrolytes, nutrients, and medications.

Therefore, a further object of the invention is a medicinal�first means, comprising an aqueous balanced electrolyte solution and optionally one or more additional components selected from the group consisting of amino acids, carbohydrates, vitamins, minerals, hydroxyethyl starch, gelatin, albumin, and intended for infusion drugs, preferably selected from the group consisting of antibiotics, analgesics, sedatives, neuroleptics, opioid funds, muscle relaxants, catecholamines and other actors through the circulation of medicines.

A medicament according to the invention is preferably a medicament for the treatment of hypotonic or isotonic dehydration, for the treatment of extracellular fluid loss, for the treatment of hypovolemia or shock, and for rehydration interstitial tissue after colloid replacement volume.

Following the subject of this invention is a method of applying water is full of electrolyte solution as an external wash solution, for example, for washing and cleaning for a surgical procedure for flushing and cleaning wounds and burns, for washing body cavities, Eyewash, for washing and cleaning tools and for maintenance Stom or as a solution carrier for compatible electrolytes, nutrients in�substances and medicines.

EXAMPLES

In the following table 2 examples are solutions of the electrolyte according to the invention.

Table 2
Examples of preparation
ComponentsExample 1Example 2Example 3Example 4
Sodium chloride5,815 g6,195 g5,639 g5,902 g
Sodium acetate × 3H2O3,266 g2,314 g2,382 g3,539 g
The sodium hydrogen phosphate × 2H2O0,156 g0,156 g0,156 g0,234 g
Sodium salt of D-gluconic acid3,817 g4,799 g5,454 g3,381 g
Potassium chloride0,298 g-0,186 g 0,186 g
Potassium acetate-0,491 gEnds 0.245 g0,196 g
D-calcium gluconate × H2O0,561 g0,897 g0,224 g0,561 g
Magnesium chloride × 6H2O0,203 g0,203 g0,305 g0,254 g
aqua ad iniectabiliato 1000 mlto 1000 mlto 1000 mlto 1000 ml

The above substances in approximately the amounts indicated fully dissolved in (water for injection) with stirring. Then set the pH value using a mixture of 10 ml of 2N hydrochloric acid and 5 ml of 2N acetic acid to pH = 6,5, volume complementaqua ad iniectabila(water for injection) to 1000 ml and the solution poured into a glass bottle for infusion 250 ml, supply tube and folded edge. Bottles are sterilized is known, the relevant state of the art method (for example, 20 minutes at 121°C).

1. The use of balanced water dissolve�and electrolytes with ions content:
a) 138-146 mmol/l sodium,
b) 4-5 mmol/l potassium,
c) from 0.5-2.0 mmol/l calcium,
(d) is 1.0-1.5 mmol/l magnesium
e) 100-108 mmol/l of chloride,
f) 0.5 to 1.5 mmol/l phosphate,
(g) from 18 to 26 mmol/l gluconate and
h) 20-28 mmol/l acetate,
as an external wash solution for washing and cleaning for a surgical procedure for flushing and cleaning wounds and burns, for washing body cavities, Eyewash, for washing and cleaning tools and for maintenance Stom or as a solution carrier for compatible electrolytes, nutrients, and medications.

2. The use according to claim 1, wherein the water balanced electrolyte solution includes 140-144 mmol/l sodium.

3. The use according to claim 1 or 2, where water balanced electrolyte solution includes a 4.3-to 4.7 mmol/l of potassium.

4. The use according to claim 1, wherein the water balanced electrolyte solution consists of 1.0-1.5 mmol/l of calcium.

5. The use according to claim 1, wherein the water balanced electrolyte solution includes 1,1-1,4 mmol/l of magnesium.

6. The use according to claim 1, wherein the water balanced electrolyte solution comprises 102 to 106 mmol/l of chloride.

7. The use according to claim 1, wherein the water balanced electrolyte solution comprises 0.8 to 1.2 mmol/l phosphate.

8. The use according to claim 1, wherein the water balanced electrolyte solution further comprises (g) 20-24 mmol/l gluconate.

9. When�eenie according to claim 1, where water balanced electrolyte solution further includes (h) 22-26 mmol/l acetate.

10. The use according to claim 1, wherein the water balanced electrolyte solution has a pH value in the range from 5.0 to 8.0.

11. The use according to claim 1, wherein the water balanced electrolyte solution has a pH value in the region of 6.0 to 7.0.



 

Same patents:

FIELD: medicine.

SUBSTANCE: stellaria grass infusion is introduced to laboratory animals in a dose of 5 ml/kg of weight 20 minutes before irradiation in an ultraviolet chamber for 14 days daily.

EFFECT: stable pharmacological effect under conditions of reduction of the phytocorrection course duration.

3 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine and can be used for making a drug for removing subcutaneous fat. That is ensured by using a composition containing: at least one phospholipid, at least one glycyrrhizic acid or a glycyrrhizic acid salt, and wherein total content of phospholipids and glycyrrhizic acid or its salts makes 2-80 wt % and a weight ratio of phospholipids and glycyrrhizic acid or its salts makes from 30:1 to 0.5:1. The composition can additionally contain additives. As phospholipid, the composition contains animal or herbal phosphatidylcholine. The composition can also contain glycyrrhizic acid or potassium, sodium, ammonium or magnesium salt of glycyrrhizic acid. As an additive, the composition contains sugar, particularly glucose, or maltose, and/or their derivatives, mannitol, sorbitol or lactose. The composition contains phosphatidylcholine in a total amount of 15 to 98 wt %, preferentially 30 to 98 wt %, more preferentially 50 to 98 wt %, especially preferentially 75 to 98 wt %, and most preferentially 75 to 90 wt % of total content of phospholipids. The composition is used in the dry form, preferentially in the form of lyophilisate prepared by freezing and drying, or in the form of a solution. The composition can contain physiologically acceptable solvents, including water, normal saline, glucose solution, such monohydric alcohols, as ethanol, 2-propanol, n-propanol, such polyatomic alcohols, as glycerol and/or propane diol, such polyglycols, as polyethylene glycol and/or Miglyol, glycerol, formal, dimethylisosorbitol, natural and synthetic oils and/or esters. Diseases of subcutaneous fatty tissue can be particularly related to local fat maldistribution. Fatty tissue tumour decomposition and reduction can be also solved. The drug can be presented in the form of cream, ointment, gel, hydrogel, lotion, paste, powder or solution. Undesired unaesthetic and pathological local fat maldistribution involve lipoedema, adipose growth, abdominal adiposis, cellulites, pseudogynecomasty, "buffalo hump" in HIV-infected patients, panniculitis or nonspecific subcutaneous fat deposition. The preparation is administered by subcutaneous, intra-abdominal, intramuscular or intravenous injection. The administration is implemented by a method specified in a group consisting of ioophoresis, electroporetion and phonophoresis.

EFFECT: described invention is successfully used for the above purposes.

17 cl, 11 ex, 7 tbl, 11 dwg

FIELD: medicine.

SUBSTANCE: what is presented is using meso-tetra(3-pyridyl)bacteriochlorin of structural formula (I) as a near-infrared photosensitiser for a photodynamic therapy. Doses 1.0-2.5 mg/kg of the declared photosensitiser have provided 70-100% tumour growth inhibition, 80-131% increase in life expectancy and 25-100% animals' recovery by selective tumour collection and fast clearance.

EFFECT: high photoinduced activity on human tumour cells of various epithelial origin and high dose-dependent anti-tumour effectiveness in the animal with tumours of various origins.

5 dwg, 8 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: presented invention refers to immunology. There are disclosed versions of a dimer compound for forming a multimer capable to reproduce the effector function of aggregated IgG with identical monomers. Each monomer of the dimer comprises: a monomer of IgG2 link region or a monomer of isoleucine zipper, dimerising each of which forms a multimerising region, and at least Fc-domain monomer containing a link region, CH2 domain and CH3 domain of IgG1. What is described is a multimer compound capable to reproduce the effector function of aggregated IgG and containing two or more dimers. There are disclosed a method for changing the immune response using the dimer or multimer, as well as a multimer-based method of treating an inflammatory disease.

EFFECT: using the invention provides the new compounds capable to bind at least one FcR specified in a group consisting of: FcγRI, FcγRII, FcγRIII, FcγRIV, or their non-human version that can find application in medicine for IVIG substitution for treating a wide range of diseases, including the inflammatory and autoimmune diseases.

7 cl, 25 dwg, 5 tbl, 25 ex

FIELD: veterinary medicine.

SUBSTANCE: product comprises Lycopodium clavatum, Acidum arsenicosum, Phosphorus, Podophyllum peltatum, Thuja occidentalis, Echinacea purpurea, Silybum marianum, Selenocysteine, and the components are taken in the dilutions described below in the following ratio, in parts: Lycopodium clavatum ⌀=D1 0.004, Podophyllum peltatum ⌀ 0.003, Acidum arsenicosum ⌀=D2 0.0001, Phosphorus ⌀=D3 0.001, Thuja occidentalis ⌀ 30, Echinacea purpurea ⌀ 30, Silybum marianum ⌀ 60, Selenocysteine 0.2.

EFFECT: product has an effective stress-protective and growth-stimulating effect, it regulates the metabolism in young farm animals.

3 cl, 10 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: method for producing an agent for stimulating body cells involving preparing a mixture of aqueous solution of selenious acid and PEG 400; that is followed by preparing a mixture of hydrazine hydrochloride and PEG 400; the prepared mixtures are combined; the solution is put to dialyse against distilled water; surplus of water is driven off; the produced solution is added with hexamethylene tetramine; pH is reduced to 7.2-7.4; the method is implemented in certain circumstances.

EFFECT: producing high-effective, ecologically safe agent by the synergism of colloidal selenium and hexamethylene tetramine on body cell stimulation.

1 dwg, 2 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine and can be used for the treatment of radiation-thermal injury of an organism. For this purpose a single subcutaneous introduction of bifidumbacterin, irradiated by gamma-rays in a dose of 14.0 Gy, is carried out. Bifidumbacterin is introduced in a dose of 1.43·106 CFU/kg. After that, 10% hypericum oil is applied on the burnt region. Then a 10% hypericum cream is applied after 3-4 days.

EFFECT: method makes it possible to carry out the treatment of combined radiation-thermal injuries in an effective way with the application of available and cheap pharmacotherapeutic means.

1 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: erythrocyte cell medium is added with an aqueous solution of sodium and potassium salts of humic acids prepared on brown coal of leonardite in a dose of 10.0 mg/kg. That is incubated at a temperature of 37°C for 40 minutes before treatment with acidic haemolytic.

EFFECT: invention enables normalising the cell membrane permeability and reducing the damaged cell count under acidic haemolytic.

1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a new intensifier of the antitumour effect, which is a uracil derivative of the general formula (I) or its pharmaceutically acceptable salt. In the general formula (I) X represents a C1-5-alkylene group, and wherein one of methylene groups making an alkylene group is optionally substituted by an oxygen atom; R1 represents a hydrogen atom or a C1-6-alkyl group; R2 represents a hydrogen atom or a halogen atom; and R3 represents a C1-6-alkyl group, C2-6-alkenyl group, C3-6-cycloalkyl group, (C3-6-cycloalkyl)-C1-6-alkyl group, halogen-C1-6-alkyl group or a 5-6-merous saturated heterocyclic group with an oxygen atom as a heteroatom, a uracil derivative presented by the following formula (I). The invention also refers to a method for potentiating the antitumour action or a method of treating tumours, involving administering an effective amount of a combination of the above uracil derivative or its pharmaceutically acceptable salt and an antimetabolite in an effective amount. The antimetabolite represents an agent specified in 5-fluoruracil (5-FU), potassium tegafur/gimeracil/oteracil (TS-1), tegafur/uracil (UFT), capecitabin, 5-fluor-2'-deoxyuridine (FdUrd) and Pemetrexed.

EFFECT: preparing the intensifier of the antitumour effect.

18 cl, 10 dwg, 10 tbl, 67 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to methods of purification and health improvement of an organism. For this purpose therapeutic starvation for not fewer than 5 days in case of a 7-day programme and for not fewer than 7 days in case of a 9-day programme is carried out. The duration of a recovery period constitutes two days. Food intake is realised nine times per day each day both in the process of therapeutic starvation and in the recovery period. In the period of therapeutic starvation the first food intake includes bee products "APIGRANULES 2" in a dose of one teaspoon, "KHINAZI balm" in a dose of one teaspoon, "A-P-V" in a dose of one teaspoon, "APITOK" in a dose of one teaspoon, "Antihelm phyto" - one capsule and still mineral water - one glass. The second food intake includes a drink with ginger, lemon juice, garlic and mint, honey - one teaspoon and one glass of apple-carrot juice. The third food intake supposes an intake of bee products "APIGRANULES 2" in a dose of one teaspoon, "KHINAZI balm" in a dose of one teaspoon, "A-P-V" in a dose of one teaspoon, "Antihelm phyto" - one capsule and still mineral water - one glass. The fourth food intake includes a drink with ginger, lemon juice, garlic and mint, honey - one teaspoon and one glass of apple-carrot juice. The fifth food intake consists of tea black or green with ginger, one teaspoon of honey and one glass of apple-carrot juice. The sixth food intake consists of bee products "APIGRANULES 2" in a dose of one teaspoon, "A-P-V" in a dose of one teaspoon, "Antihelm phyto" - one capsule and one glass of still mineral water. The seventh food intake includes tea black or green with ginger, one teaspoon of honey and one glass of apple-carrot juice. The eighth food intake supposes an intake of tea black or green with ginger, one teaspoon of honey and one glass of apple-carrot juice. The ninth intake of food includes depressant tea, including mint grass, valerian root, fennel seeds, cumin seeds, epilobium or strawberry leaves and one glass of apple-carrot juice. In the recovery period in 1-st, 2-nd, 3-rd, 4-th and 6-th intakes of food the composition of products remains the same as in the process of starvation. For the fifth intake of food the patients take tea black or green with ginger, one teaspoon of honey and vegetable soup. For the seventh intake of food the patients take tea black or green with ginger, "MILK COCKTAIL WITH CHITOSAN". The eighth intake of food includes tea black or green with ginger, one teaspoon of honey, "APICAMPA" cereal. The ninth intake of food for the recovery period includes a baked apple, depressant tea. In addition, a number of procedures are carried out after each food intake during the period of therapeutic starvation and the recovery period. After the first food intake gymnastics "5 Tibetan pearls" is realised. After the second food intake exercises on training apparatuses, procedures of press-therapy, electrolypolysis and myostimulation are realised. After the third food intake exercises of therapeutic physical training or aerobics are performed. After the fourth food intake a rest in form of a walk, a halotherapy session, combined with a session of relaxation therapy are realised. After the fifth food intake a course of strip-plastic is carried out. After the sixth food intake massage by manual application with a peloid-based mixture or manual massage with honey is carried out. After the seventh food intake an infra-red sauna, shower, phytobath with medicinal herbs, honey, ginger, lemon juice is taken. After the eighth food intake a shower is taken.

EFFECT: method ensures effective health improvement of the organism with the preservation of the full value life style and a sense of a comfortable state in the starvation period, reduction of recovery period term after starvation, purification of the organism without loading on the gastrointestinal tract, weight loss, and improvement of the general state and workability of the patients.

3 tbl, 7 ex

FIELD: medicine.

SUBSTANCE: method involves pharmacological correction with 1.5% sodium succinate 'Reamberin' min 800 ml a day (12 ml/kg) that is administered intravenously drop-by-drop.

EFFECT: invention enables stabilising the patient's general health by reducing intracellular acidosis and recovering the activity of the enzymatic systems of the body.

1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, and may be used for the individual's functional state correction. That is ensured by diagnosing the functional state followed by correcting the detected disorders. Blood pH is determined when diagnosing the functional state. For the purpose of correcting the detected disorders, the conventional treatment is combined with administering a solution heated to a temperature of 36.6°C, prepared by an electrolytic reduction of a saline solution to form an anolyte and a catholyte to be mixed to prepare a solution of pH 2-10 and an oxidation-reduction potential within +1050 to -800 mV; the solution is administered into the patient to provide blood pH within 7.35-7.45.

EFFECT: invention provides the adequate individual's functional state correction in the presence of a chronic infection by the effect of an activated medium on an acid-base balance of blood and the individual's oxidation-reduction potential (ORP).

2 cl, 4 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely surgery and intensive care, and may be used in treating the patients with developed sepsis with underlying abdominal and retroperitoneal diseases. For this purpose, the management starts with a session of endotoxin absorption. That is followed by the intravenous administration of a bactericidal antibiotic, e.g. such as β-lactam or fluoroquinolone in the amount of 1.1-1.5 daily dose; then 30-60 minutes later, endotoxin sorption is combined with de-hydration hemofiltration in a dose of 45 ml/kg/h for 6-8 hours. The whole procedure is accompanied by the infusion therapy using active solutions specified in a group of low- and high-molecular hydroxyethyl starch and dextran in the amount of 5-10 ml/kg/h. Before the beginning of endotoxin sorption, as well as one day after the termination of hemofiltration and sorption, the blood endotoxin concentration is controlled. If the recorded endotoxin concentration is decreased at least by 60%, another procedure is performed.

EFFECT: method provides higher survival rate in the patients suffering the above pathology, as well as reduces a risk of septic shock ensured by the pathogenically caused regimen of the combination of various human body effects providing a degree of systemic endotoxemia to be decreased.

2 cl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to gastroenterology, and concerns a reducing diet therapy. A patient takes a saline laxative and stops food intake. Stating from first day of fast, 1.5-2 l of purified water is introduced daily in equal portions, with administering at the end of the day a cleansing enema of 1.5-2 l of purified water with colloidal silver added at 10 drops per 1 l. Psychotherapeutic discussion, walks for 30-40 minutes 2-3 times a day and Nishi gymnastics are practiced. Starting from the second day of fast, for 16 days, daily at 7:30 the patient takes 1/3 teaspoons of a vegetative organic sorbent dissolved in a glass of water with another glass of water taken in half an hour thereafter. At 9:30 and 18:30, an herbal antihelmintic drug is administered; 9:40 and 18:40, 1 capsule of an herbal preparation "Catrel" is taken. At 10:00 and every night at bedtime, colloidal silver is taken in amount 1 teaspoon, held in a mouth for 6 minutes, then swallowed and also instilled 1 drop in each eye and 1 drop in nose. During a day, herbal tea "Pohudey-ka", "Cleansing", and every night at bedtime, 2 tablets of "Senade" are prescribed. On 3rd, 6th, 10th, 13th, 16th days of fast, every night at bedtime, liver and gall bladder flush is performed. The course involves 3-5 procedures of hydrocolonotherapy. The first days of the recovery period, the patient consumes fresh juices, vegetables, fruits, bacterial preparation "Bacteriobalance", with a vegetarian salt-free diet for a month. Starting from the third day, vitamin-mineral and microelement complexes containing organic calcium, selenium, iodine, polyunsaturated fat acids, and essential amino acids are prescribed.

EFFECT: method provides effective complex normalisation of digestive organs activity and thereby health improvement.

4 cl, 4 ex

FIELD: medicine; pharmacology.

SUBSTANCE: application [desamino-1, isoleucine-3, arginine-8]-vasopressin is offered. Means surpasses arginine-8-vasotocin in the declared activity and its application can find at hypernatremia.

EFFECT: increase in excretion of salts of sodium by kidney and strengthening of return selective absorption from uriniferous tubules in water-solvent blood.

1 tbl

Antidiabetic agent // 2283659

FIELD: pharmaceutical industry, veterinary, plant therapy, food processing industry.

SUBSTANCE: invention relates to agent from plant raw materials useful in prophylaxis ant therapy of diabetus mellitus. Claimed agent contains (mass pts): Galega officinalis grass 8-12; nettle leaves 0.5-1.5; dandelion root 0/5-1.5; dogrose fruits 0.5-2.0; burdock root 0.5-2.0; desiccated carrot 40.0-50.0; fructose or sorbitol 40.0-50.0.

EFFECT: agent reducing blood cholesterol and uric acid levels and releasing oxalic and uric acid salts from organism.

1 ex

The invention relates to the field of pharmaceutical industry

The invention relates to medicine, in particular to a gastroenterologist, and for increasing the absorption of minerals in the gut

FIELD: chemistry.

SUBSTANCE: invention relates to the field of organic chemistry, namely to derivatives of diaza-spiro[4.5]decan-1-one of formula (I) or to their pharmaceutically acceptable salts, where. R1 is a substituted phenyl, which contains one substituent, selected from the group, including C1-4-alkyl, C3-6-cycloalkyl halo-C1-4-alkyl and halo -C1-4-alkoxy, and which can additionally contain one substituent, selected from a halogen; R2 is hydrogen, C1-4-alkyl, phenyl, substituted phenyl, with the substituted phenyl containing one substituent, selected from the group, including C1-4-alkoxy; R3 is -R4, -C(OH)R5R6 or -C(O)NR7R8; R4 is phenyl, phenyl-C1-4-alkyl, substituted phenyl, substituted phenylcarbonyl, with the substituted phenyl, substituted phenylcarbonyl containing from one to two substituents, selected from the group, including a halogen, halo-C1-4-alkyl; one of R5 and R6 is hydrogen, C1-4-alkyl, and the other is aminocarbonyl, phenyl, substituted phenyl or substituted phenyl-C1-4-alkyl, with the substituted phenyl or substituted phenyl-C1-4-alkyl containing from one to two substituents, independently selected from the group, including a halogen; one of R7 and R8 is hydrogen C1-4-alkyl, and the other is C1-4-alkyl, C3-6-cycloalkyl, C1-4-alkoxy-C1-4-alkyl, phenyl-C1-4-alkyl, substituted phenyl or substituted phenyl-C1-4-alkyl, with the substituted phenyl or substituted phenyl-C1-4-alkyl containing one substituent, selected from the group, including a halogen, halo-C1-4-alkyl; or R7 and R8 together with a nitrogen atom, which they are bound to, form pyrrolidinyl; n equals zero or 1/ The invention also relates to a pharmaceutical composition based on the compound of formula (I), application of the formula (I) compound and a method of treatment.

EFFECT: obtained are novel heterocyclic compounds, useful as an inhibitor of hormone-sensitive lipase.

17 cl, 57 ex

FIELD: veterinary medicine.

SUBSTANCE: product comprises Lycopodium clavatum, Acidum arsenicosum, Phosphorus, Podophyllum peltatum, Thuja occidentalis, Echinacea purpurea, Silybum marianum, Selenocysteine, and the components are taken in the dilutions described below in the following ratio, in parts: Lycopodium clavatum ⌀=D1 0.004, Podophyllum peltatum ⌀ 0.003, Acidum arsenicosum ⌀=D2 0.0001, Phosphorus ⌀=D3 0.001, Thuja occidentalis ⌀ 30, Echinacea purpurea ⌀ 30, Silybum marianum ⌀ 60, Selenocysteine 0.2.

EFFECT: product has an effective stress-protective and growth-stimulating effect, it regulates the metabolism in young farm animals.

3 cl, 10 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to the field of organic chemistry, namely to novel derivatives of pyrazole pyridine of formula , as well as to its tautomers, geometrical isomers, enantiomers, diastereomers, racemates and pharmaceutically acceptable salts, where G1 represents H; G2 represents -CHR1R2; R1 and R2 independently on each other are selected from H; C1C6-alkoxy-C1C6-alkyl; C1-C6-alkyl; optionally substituted phenyl; optionally substituted phenyl-C1-C6-alkyl; optionally substituted morpholine-C1-C6-alkyl; or -CHR1R2 together form a ring, selected from an optionally substituted C3-C8-cycloalkyl and substituted piperidine; G3 is selected from an optionally substituted C1C6-alkoxy -C1-C6-alkyl; C1-C6-alkyl; substituted phenyl; substituted phenyl-C1C6-alkyl; G4 is selected from a substituted acyl-C1C6-alkyl, where acyl represents a group -CO-R and R stands for H or morpholine; optionally substituted C1-C6-alkyl; optionally substituted phenyl or indene; substituted phenyl-C1-C6-alkyl; optionally substituted pyridine- or furanyl-C1C6-alkyl; morpholine- or piperidine-C1-C6-alkyl; G5 represents H; where the term "substituted" stands for the groups, substituted with 1 to 5 substituents, selected from the group, which includes a "C1-C6-alkyl," "morpholine", "C1-C6-alkylphenyl", "di-C1-C6-alkylamino", "acylamino", which stands for the group NRCOR", where R represents H and R" represents a C1-C6-alkyl, "phenyl", "fluorine-substituted phenyl", "C1-C6-alkoxy", "C1-C6-alkoxycarbonyl", "halogen". The invention also relates to a pharmaceutical composition based on the formula (I) compound and particular compounds.

EFFECT: obtained are the novel derivatives of pyrasole pyridine, useful for the treatment and/or prevention of disorders or states, associated with NADPH-oxidase.

12 cl, 3 tbl, 21 ex

Up!